Visa Inc. (NYSE:V) - Analysts at Jefferies Financial Group raised their FY2021 earnings per share (EPS) estimates for shares of Visa in a report released on Thursday, April 15th. Jefferies Financial Group analyst T. Williams now anticipates that the credit-card processor will post earnings per sh
Daimler AG (OTCMKTS:DDAIF) - Equities research analysts at Jefferies Financial Group issued their Q1 2021 earnings per share estimates for shares of Daimler in a note issued to investors on Wednesday, April 14th. Jefferies Financial Group analyst P. Houchois expects that the company will earn $2.
Moderna, Inc. (NASDAQ:MRNA) - Equities research analysts at Jefferies Financial Group dropped their Q3 2021 earnings per share estimates for shares of Moderna in a research note issued on Wednesday, April 14th. Jefferies Financial Group analyst M. Yee now anticipates that the company will post ea
Community Health Systems, Inc. (NYSE:CYH) - Research analysts at Jefferies Financial Group raised their Q2 2021 earnings per share (EPS) estimates for shares of Community Health Systems in a report issued on Wednesday, April 14th. Jefferies Financial Group analyst B. Tanquilut now expects that th
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) - Research analysts at Jefferies Financial Group upped their Q4 2021 earnings estimates for Walgreens Boots Alliance in a report released on Wednesday, April 14th. Jefferies Financial Group analyst B. Tanquilut now forecasts that the pharmacy operator w
Fiserv, Inc. (NASDAQ:FISV) - Analysts at Jefferies Financial Group upped their Q2 2021 earnings per share (EPS) estimates for shares of Fiserv in a research report issued to clients and investors on Thursday, April 15th. Jefferies Financial Group analyst T. Williams now expects that the business
LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in an analyst-led fireside chat on Thursday, April 22 at the Jefferies Microbiome-Based Therapeutics Summit.
Global insured losses from catastrophes so far this year are nearly 40% above average, according to Jefferies' equity research analysts.
Investors in Jefferies Group Inc. (Symbol: JEF) saw new options become available today, for the December 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 246 days until expiration the newly avail
Alan Spence from Jefferies retains his positive opinion on the stock with a Buy rating. The target price is unchanged and still at EUR 34. | April 15, 2021
Several European banks' noses were put out of joint this week by research from Jefferies, which suggested a very different ranking of banks' ESG characteristics from that investors usually get from rating providers. The study argued commercial ESG ratings on banks are not fit for purpose.
In a research note, Jefferies analyst Martin Comtesse has maintained his recommendation on the stock with a Buy rating. The target price is still set at EUR 118. | April 15, 2021
5 hours ago (Apr 15, 2021 12:25PM ET) Jefferies (NYSE:) analyst Ken Usdin maintained a Sell rating on First Republic Bank (NYSE:) on Thursday, setting a price target of $163, which is approximately 5.84% below the present share price of $173.11.
8 hours ago (Apr 15, 2021 08:37AM ET) Jefferies (NYSE:) analyst Corey Tarlowe maintained a Hold rating on Dollar Tree (NASDAQ:) on Tuesday, setting a price target of $117, which is approximately 1.83% above the present share price of $114.9. Tarlowe expects Dollar Tree to post earnings per share (EPS) of $2.14 for the second quarter of 2021.
9 hours ago (Apr 15, 2021 08:15AM ET) Jefferies (NYSE:) analyst David Katz maintained a Buy rating on Six Flags (NYSE:) on Wednesday, setting a price target of $56, which is approximately 20.12% above the present share price of $46.62. Katz expects Six Flags to post earnings per share (EPS) of -$1.00 for the second quarter of 2021.
Citigroup (NYSE:C) had its price objective raised by equities research analysts at Jefferies Financial Group from $75.00 to $85.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Jefferies Financial Group's price target would suggest a potential upside of 16.58% from the company's current price.
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Expedia Group, Inc. (NASDAQ:EXPE) - Research analysts at Jefferies Financial Group raised their Q1 2021 EPS estimates for Expedia Group in a report issued on Tuesday, April 13th. Jefferies Financial Group analyst B. Thill now forecasts that the online travel company will post earnings of ($2.77)
Moderna, Inc. (NASDAQ:MRNA) - Equities research analysts at Jefferies Financial Group dropped their Q3 2021 earnings per share estimates for shares of Moderna in a research note issued on Wednesday, April 14th. Jefferies Financial Group analyst M. Yee now anticipates that the company will post ea
GlaxoSmithKline plc (NYSE:GSK) - Jefferies Financial Group boosted their Q2 2021 earnings per share estimates for shares of GlaxoSmithKline in a report released on Wednesday, April 14th. Jefferies Financial Group analyst P. Welford now anticipates that the pharmaceutical company will earn $0.59 p